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Abstract
Background Hidradenitis suppurativa (HS), also known as acne inversa, is a recurring, painful, chronic, and sometimes 
disfiguring inflammatory skin disease.
Objectives Our objective was to report the baseline clinical characteristics, natural history, and associated outcomes of 
patients with HS from the ongoing, prospective, non-interventional UNITE registry that is collecting data regarding the 
natural history and associated outcomes of HS.
Methods Patients with inflammatory HS lesions were enrolled, including adolescents (aged 12 to < 18 years) and adults 
(aged ≥ 18 years). None had participated in previous or current originator-adalimumab studies/registries. Patients received 
treatment consistent with site-specific, routine clinical practice. HS disease status was assessed by HS lesions and disease 
flare; treatment and outcomes data were collected at enrolment and every 6 months for ≤ 4 years.
Results Enrolment (N = 594; 89.1% adults; 10.9% adolescents) occurred from 29 October 2013 to 29 December 2015 at 
73 sites in 12 countries. At baseline, the majority were female (69.7%) and White (81.2%), had moderate-to-severe disease 
(Hurley stage II or III; 93.3%), and had undergone prior procedures/surgery for HS (68.7%). In total, 61.6% of adults and 
49.2% of adolescents were obese; 40.2% of patients reported current tobacco use. Scarring due to lesions occurred in 91.2% 
of patients. The prevalence of comorbidities of interest was as follows: depression (13.3%), other psychiatric disorders (9.6%), 
inflammatory bowel disease (2.7%), diabetes (9.1%), and polycystic ovary syndrome (5.2%).
Conclusions In this population from the UNITE HS registry, obesity and smoking were common, and disease burden was 
high, manifesting as multiple lesions, scarring, surgical history, and considerable comorbidities.
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Key Points 
This report of the baseline characteristics from UNITE, 
a non-interventional long-term hidradenitis suppurativa 
(HS) registry, provides the first geographically diverse, 
detailed clinical description of HS in an observed popu-
lation across North America, Europe, and Australia.
Clinical aspects of the disease appeared similar between 
adults and adolescents, although adolescents were more 
likely to have been diagnosed earlier in the disease 
course.
Lesion count and scarring affected the groin/pelvic/pubic 
area most commonly and severely compared with the 
inframammary area, in contrast to previous reports.
 E. P. Prens et al.
1 Introduction
Hidradenitis suppurativa (HS; or acne inversa) is a chronic, 
inflammatory skin disease that manifests as inflammatory 
nodules, abscesses, draining fistulas, and—in some cases—
severe scarring [1]. The disease affects mainly intertriginous 
areas (axillae, inguinal, genital, and inframammary regions), 
which are subject to friction [1, 2].
HS occurs about three times more frequently in women 
than in men [3–6]. The estimated prevalence is 0.1% based 
on US claims data and approximately 1–4% in Europe [7, 
8]. Clinical experience suggests that HS is under-recog-
nised, especially among the non-dermatology community 
[9], which frequently results in substantial delay in diag-
nosis (≥ 7 years average) [10, 11]. Onset is generally post-
pubertal (20–30 years of age) [4] but can rarely occur in 
prepubescence [5]. The disease is diagnosed by the presence 
of characteristic lesions in typical body sites, but there is no 
confirmatory diagnostic test [12]. Adults and adolescents 
share the clinical features of HS.
Although not fully understood, the pathogenesis of HS is 
thought to be a combination of genetic, environmental, and 
physiological factors, including auto-inflammatory mecha-
nisms and microbiome alterations [11], and may also be 
related to follicular occlusion, inflammation, and abnormal 
immune response in the skin [1, 13, 14].
HS greatly impacts quality of life [12, 15–18], and disease 
burden can be substantial, especially as severity increases. 
The malodorous discharge from draining lesions can cause 
embarrassment, psychological stress, and social stigma, 
which may lead to social isolation [9]. Pain from active 
lesions can substantially impair quality of life and lead to 
work disability [16]. Symptoms can also be caused by irre-
versible scarring, which can limit physical activity and cause 
psychological impairment [19]. Noncutaneous comorbidi-
ties can also be significantly burdensome [20] and include 
depression, arthritis (including spondyloarthropathies), 
metabolic syndrome, polycystic ovary syndrome (PCOS), 
obesity, skin cancer, and inflammatory bowel disease [7, 
11, 12, 21, 22].
Treatment for HS is typically individualised based on 
clinical presentation and disease impact [23]. Evidence-
based treatments include anti-inflammatory antibiotics (topi-
cal clindamycin, then oral doxycycline or minocycline) and 
adalimumab (the only approved pharmacological treatment 
for HS). Less well-researched treatments include zinc glu-
conate, topical resorcinol, intralesional and systemic corti-
costeroids, acitretin, and infliximab. Other agents with lim-
ited levels of supporting evidence include hormone therapy, 
cyclosporine, dapsone, and others [24, 25]. Classical sur-
gery and/or laser techniques can be combined with medical 
therapy and may be appropriate for locally recurring lesions 
and for severe disease [26]. Adjuvant measures include pain 
management, treatment of superinfections, weight loss, and 
tobacco abstinence [24].
Improved characterisation of the natural history, diag-
nostic patterns, and clinical characteristics of HS could 
inform the development of treatments and improve patient 
care. To that end, UNITE is the first geographically 
diverse, longitudinal, prospective, observational registry 
to collect long-term clinical and health-related quality-
of-life data from patients with HS. The objective of this 
ongoing registry is to evaluate the natural history and risk 
of progression of HS, evolving clinical practice trends, 
and associated outcomes in patients with HS. We report 
UNITE’s baseline demographic and clinical character-
istics for adult and adolescent patients with HS. Base-
line patient-reported outcomes from UNITE, including 
comprehensive quality-of-life outcomes, are published 
separately [27].
2  Materials and Methods
2.1  Study Design
In this non-interventional registry, patient treatment is ren-
dered per routine clinical practice at each site. The protocol 
does not mandate using specific medication(s) or treatment 
procedure(s). Data on HS treatment and associated clini-
cal and patient-reported outcomes were collected at enrol-
ment and approximately every 6 months thereafter for up 
to 4 years. As this registry is observational, no pre-defined 
hypotheses exist regarding the magnitude of any resulting 
differences.
2.2  Patients
Approximately 500–600 patients were to be enrolled from 
75–100 sites across 12 countries. UNITE’s sample size was 
based on the size needed for a reliable assessment of the 
descriptive statistics. Adolescents (aged 12–18 years) and 
adults (aged ≥ 18 years) with a confirmed diagnosis of HS, 
presence of HS inflammatory nodules and/or abscesses, 
and no previous or current participation in an adalimumab 
clinical study or registry were enrolled. To minimise poten-
tial bias in outcome measurement due to varying levels of 
disease severity, the registry attempted to enrol a balanced 
proportion of adults across Hurley stages I, II, and III (mild, 
moderate, and severe disease, respectively); given the lower 
numbers of adolescents enrolled, balance across stages was 
not attempted.
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2.3  Baseline Characteristics
The last non-missing measurement collected at or before 
enrolment was used as the baseline for summary of demo-
graphics, disease characteristics, and disease activity. 
Adverse events were not prospectively collected since this 
is a non-drug, non-interventional disease registry. No routine 
laboratory results were collected.
The clinical course of HS was assessed by lesions located in 
the overall body areas and in the anatomic region within each 
body area, as defined in Online Resource 1. The following were 
assessed at enrolment: lesions and hypertrophic scarring, lesion 
type (abscess, inflammatory nodule, non-inflammatory nod-
ule, draining fistula, and non-draining fistula), lesional drainage 
requiring use of pad(s), and frequency of HS flares. “Flare” was 
identified by the investigator and patient.
2.4  Statistical Analysis
All baseline characteristics were summarised by descriptive 
statistics. Means and standard deviations (SDs) were reported 
for continuous variables; count and proportion were reported 
for categorical variables. Analyses were conducted for all 
enrolled in the registry. When appropriate, results were also 
reported by age group (adolescents and adults) and/or by base-
line Hurley stage. All statistical analyses were conducted in 
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
3  Results
Enrolment started on 29 October 2013 and completed on 29 
December 2015. As of 24 September 2018, most patients 
had participated in the registry for ≥ 3.5 years. A total of 
594 patients were enrolled from 73 sites in 12 countries: 
USA (323; with an additional 10 in Puerto Rico), Canada 
(76), Netherlands (36), Germany (35), Spain (32), Italy (30), 
Hungary (14), Greece (11), Switzerland (11), Australia (8), 
France (5), and Czech Republic (3).
3.1  Patient Characteristics at Baseline
The majority of patients were adults (89.1%, N = 529), of 
whom 97.7% were aged < 65 years and 10.9% (N = 65) were 
adolescents (Table 1). The mean age was 36.1 years. Most 
patients were female (69.7%) and White (81.2%). Current or 
previous tobacco use was reported by 64.1% of adults and 
6.1% of adolescents. Current tobacco use was reported by 
40.2% of all patients and increased with increasing disease 
severity (32.5%, 39.8%, and 43.1% at Hurley stages I, II, and 
III, respectively).
The majority (83.7% of adults and 75.4% of adolescents) 
were overweight to obese, defined as body mass index (BMI) 
≥ 25 kg/m2 for adults and ≥ 85th percentile for adolescents. 
Most adults (61.6%) and almost half of adolescents (49.2%) 
were obese (BMI ≥30 kg/m2 for adults and BMI ≥95th per-
centile for adolescents) (Table 2).
3.2  Disease Characteristics at Baseline
The majority of patients had Hurley stage II disease (65.4% 
of adults and 73.8% of adolescents; Table 3). In addition, a 
higher proportion of adults (94.7%) than adolescents (81.5%) 
had Hurley stage II or III disease. The median/mean time 
between onset of HS symptoms and diagnosis was 4.1/8.3 
years for adults and 1.3/2.5 years for adolescents (Table 3). 
Approximately one-third of patients reported a family his-
tory of HS (30.1% adults, 35.4% adolescents).
Patients had substantial disease burden based on 
mean ± SD lesion counts and number of flares (Table 3). 
Among lesions, nodules were most frequent overall 
(6.9 ± 10.7 inflammatory and 6.9 ± 18.4 non-inflammatory). 
Flares during the 6 months before baseline were 5.8 ± 9.5 
for adults (approximately one flare/month) and 4.6 ± 5.6 for 
adolescents. More than one-third of patients (38.7%) used 
pads for lesional drainage.
Mean total lesion count was highest in the pelvic/pubic/
genital region compared with other body areas (Fig. 1). 
Mean total lesion count was highest in each body area at 
Hurley stage III for adults (Fig. 1a) but Hurley stage II for 
adolescents (Fig. 1b). The pelvic/pubic/genital region had 
the highest total mean ± SD abscess and inflammatory nod-
ule (AN) count (6.6 ± 11.7) and total fistula (draining and 
non-draining) count (5.9 ± 14.7) compared with other body 
areas (Fig. 1c). Patients at Hurley stage III had the highest 
AN and fistula counts (18.7 ± 24.9 and 19.6 ± 40.7, respec-
tively; Fig. 1d).
Scarring due to HS was reported by 91.2% of patients 
overall and was more common in adults than in adolescents 
(92.8% and 78.5%, respectively). Scarring increased with 
Hurley stage (4.7%, 97.2%, and 100% for Hurley stage I, 
II, and III, respectively; Table 4). The most common areas 
affected by scarring were pelvic/pubic/genital, followed by 
axilla (69.4% and 60.8% of patients, respectively).
3.3  Comorbidities at Baseline
The most common comorbidities were hypertension (14.3% 
of all patients), depression (13.3%), and other cognitive/
psychiatric disorders, including anxiety (9.6%) (Table 5). 
Notable skin manifestations included pilonidal cyst (7.1% 
of patients), contracture, or strictures due to HS scarring 
(4.5%), severe acne (4.2%), and acne conglobata (2.7%). 
Metabolic conditions included diabetes mellitus (9.1%) and 
hyperlipidaemia (5.9%). Inflammatory bowel disease was 
reported in 2.7% of all patients, and 5.2% had PCOS.
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3.4  Treatment Before Enrolment
The proportion of adults reporting a prior procedure/surgery 
for HS (72.4%) was higher than the proportion of adoles-
cents (38.5%; Table 6). Similar proportions of adults and 
adolescents had used prior medication for HS (73.9% and 
67.7%, respectively; Table 7). Overall, a majority (68.7%) 
had one or more prior procedure/surgery for HS; the most 
common was incision and drainage by a physician (33.8%). 
The proportion of patients reporting any prior HS procedure/
surgery was higher at Hurley stage II or III (70.0%) than at 
Hurley stage I (50.0%; Table 6).
The majority of patients (73.2%) had received prior medi-
cation for HS (Table 7). The most common medication cat-
egory was antibiotics (68.4% overall; 69.0% adults, 63.1% 
adolescents), with retinoids (17.7%; topical vs. oral was 
not specified), corticosteroids (8.8%), hormonal therapies 
(4.4%), and immunosuppressants (1.3%) also reported. Only 
5.5% of adults, and no adolescents, had been prescribed a 
biologic. Opioid use was reported by 1.3% of all patients. 
The main reason for discontinuation of prior medication for 
HS was inadequate response (55.5% overall; 56.9% adults, 
42.6% adolescents).
3.5  Quality of Life
Patient quality of life was captured for 529 adults using the 
Dermatology Life Quality Index (DLQI) (mean score ± SD 
12.6 ± 8.0) and for 65 adolescents using the Children’s 
Table 1  Baseline demographics
Data are presented as mean ± standard deviation or N (%) unless otherwise indicated
NC data not collected
a Missing data (two and three adolescents at Hurley stage I and II, respectively)
b Tobacco use unknown (two adults at Hurley stage II)
c Alcohol use unknown (13 adults: two, eight, and three at Hurley stage I, II, and III, respectively; one adolescent at Hurley stage I)
Characteristics Adults
N = 529
Adolescents
N = 65
All patients
N = 594
All patients, by Hurley stage
I (N = 40) II (N = 394) III (N = 160)
Sex
 Male 166 (31.4) 14 (21.5) 180 (30.3) 11 (27.5) 105 (26.6) 64 (40.0)
 Female 363 (68.6) 51 (78.5) 414 (69.7) 29 (72.5) 289 (73.4) 96 (60.0)
Racea
 White 425 (80.3) 53 (88.3) 478 (81.2) 31 (81.6) 330 (84.4) 117 (73.1)
 Black 88 (16.6) 7 (11.7) 95 (16.1) 7 (18.4) 52 (13.3) 36 (22.5)
 Asian 11 (2.1) 0 11 (1.9) 0 7 (1.8) 4 (2.5)
 Native Hawaiian or Pacific Islander 2 (0.4) 0 2 (0.3) 0 1 (0.3) 1 (0.6)
 American Indian or Alaskan Native 2 (0.4) 0 2 (0.3) 0 1 (0.3) 1 (0.6)
 Multi-race 1 (0.2) 0 1 (0.2) 0 0 1 (0.6)
Ethnicity
 Hispanic or Latino 65 (12.3) 6 (9.2) 71 (12.0) 8 (20.0) 46 (11.7) 17 (10.6)
Age, years 38.6 ± 12.57 15.6 ± 1.38 36.1 ± 13.88 NC NC NC
Age categories, years
 12 to ≤ 17 0 65 (100) 65 (10.9) 12 (30.0) 48 (12.2) 5 (3.1)
 18 to < 40 296 (56.0) 0 296 (49.8) 14 (35.0) 203 (51.5) 79 (49.4)
 40 to ≤ 64 221 (41.8) 0 221 (37.2) 13 (32.5) 134 (34.0) 74 (46.3)
 ≥ 65 12 (2.3) 0 12 (2.0) 1 (2.5) 9 (2.3) 2 (1.3)
Tobacco  useb
 User 235 (44.6) 3 (4.6) 238 (40.2) 13 (32.5) 156 (39.8) 69 (43.1)
 Former user 103 (19.5) 1 (1.5) 104 (17.6) 7 (17.5) 70 (17.9) 27 (16.9)
 Non-user 189 (35.9) 61 (93.8) 250 (42.2) 20 (50.0) 166 (42.3) 64 (40.0)
Alcoholc
 User 279 (54.1) 3 (4.7) 282 (48.6) 15 (40.5) 193 (50.0) 74 (47.1)
 Former user 63 (12.2) 0 63 (10.9) 2 (5.4) 37 (9.6) 24 (15.3)
 Non-user 174 (33.7) 61 (95.3) 235 (40.5) 20 (54.1) 156 (40.4) 59 (37.6)
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DLQI (CDLQI) (mean score ± SD 6.9 ± 6.2). In adults, 
the mean ± SD DLQI score by Hurley stages I, II, and III 
was 8.8 ± 7.3 (N = 28), 11.6 ± 7.5 (N = 346), and 15.7 ± 8.2 
(N = 155), respectively. In adolescents, the mean ± SD 
CDLQI score by Hurley stages I, II, and III was 5.5 ± 6.2 
(N = 12), 6.6 ± 6.0 (N = 48), and 12.8 ± 6.2 (N = 5), respec-
tively. A thorough description of additional quality-of-life 
and other patient-reported outcomes from UNITE are pub-
lished separately [27].
4  Discussion
The ongoing UNITE registry is the first global, longitudinal, 
prospective, observational registry collecting long-term clin-
ical and quality-of-life data for patients with HS. Baseline 
data confirm that the burden of HS is substantial, especially 
with more severe disease. Patients had multiple comorbidi-
ties and generally received multiple treatments before enrol-
ment. The majority were female and White, and the mean 
age was 36.1 years, which is similar to that in other reports 
of HS populations [7, 22, 28, 29].
Results suggest that patients may have been at a more 
advanced disease stage by the time they saw a dermatolo-
gist; 93.3% were at Hurley stage II or III and—consistent 
with other reports [10, 11, 28, 29]—the average time from 
symptom start to disease diagnosis was 7.7 years overall 
(adults 8.4 years; adolescents 2.5 years). The shorter time for 
adolescents suggests a greater likelihood of timely diagnosis 
despite having, on average, less severe disease. The mean 
age at start of symptoms was fairly young (23.2 years over-
all; adults 24.5, adolescents 12.1).
A strong heritable component was observed for HS in 
UNITE; 30.6% reported a family history of HS (adolescents 
35.4% vs. adults 30.1%), similar to other reported findings 
[28, 30]
The burden of disease at baseline in UNITE was evalu-
ated by examining lesions, scarring, comorbidities, prior 
medical treatments, and quality of life. Although the axilla is 
reportedly the area most commonly affected with HS lesions 
[28, 29, 31], the highest mean number of lesions overall in 
UNITE was observed in the pelvic/pubic/genital region, fol-
lowed by axillary and mammary regions. Scarring was also 
most common in the pelvic/pubic/genital region (69.4% of 
patients); 60.8% had axillary scarring. Over 90% of patients 
had some degree of scarring at baseline. Nearly 5% of those 
classified as having Hurley stage I disease had scarring at 
baseline; by Hurley stage definition, these patients were 
under-classified, suggesting that severity can be overlooked 
in HS. Scarring is one of the major components of disease 
burden. In a qualitative study, 80.9% of patients reported 
psychological symptoms and 38.1% reported physical symp-
toms or limitations due to scarring [19]. Thus, it is critical to 
manage HS aggressively across Hurley stages to minimise 
the potential for irreversible damage.
Smoking and obesity have been identified as major risk 
factors associated with HS and as factors that are likely 
to increase disease severity [7, 32]. Patients with HS are 
Table 2  Baseline body weight and body mass index
Data are presented as mean ± standard deviation or N (%) unless otherwise indicated
BMI body mass index
Characteristics Adults
N = 529
Adolescents
N = 65
All patients
N = 594
Body weight, kg
 Male (N=166)
100.7 ± 26.00
(N = 14)
87.9 ± 21.45
(N = 180)
99.7 ± 25.86
 Female (N = 361)
93.7 ± 23.96
(N = 51)
75.9 ± 20.68
(N = 412)
91.5 ± 24.28
BMI, kg/m2 (N = 526)
33.2 ± 8.10
(N = 64)
28.1 ± 6.43
(N = 590)
32.6 ± 8.08
BMI kg/m2 categories Adults (N = 526)
 < 25 Normal weight 86 (16.3)
 25 to < 30 Overweight 116 (22.1)
 30 to < 40 Obese 219 (41.6)
 ≥ 40 Morbidly obese 105 (20.0)
BMI percentile categories Adolescents (N = 61)
 < 5th Underweight 0
 5th to < 85th Normal weight 15 (24.6)
 85th to < 95th Overweight 16 (26.2)
 ≥ 95th Obese 30 (49.2)
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13-fold more likely to be smokers and 4.4-fold more likely 
to be obese than are matched controls [7]. In UNITE, a 
substantial number of patients were current tobacco users 
at baseline, as also reported in other HS populations [7, 
22, 28, 29]. Overall, the reported use at baseline increased 
as disease severity increased (measured by Hurley stage), 
a relationship also observed in another study [33]. Most 
UNITE patients were above normal weight, and the major-
ity of those were obese, similar to baseline characteris-
tics from a US-specific report of patients with HS [29]. 
However, two studies in France reported that just under 
half were overweight or obese, suggesting a potential geo-
graphical difference in obesity among patients with HS 
[7, 28]. In UNITE, a complete analysis of body weight 
or BMI by country of study site was not possible, as the 
majority of patients were enrolled in North America (USA 
and Canada).
The most common medical condition in UNITE was 
hypertension (14.3%); diabetes mellitus was reported 
by 9.1% of patients and hyperlipidaemia by 5.9%. These 
rates are lower than expected based on other reports [22, 
34]. Approximately 2.7% of UNITE patients had a medical 
Table 3  Baseline characteristics associated with hidradenitis suppurativa
Data are presented as mean ± standard deviation or N (%) unless otherwise indicated
HS hidradenitis suppurativa, ISH4 International Hidradenitis Suppurativa Severity Score System, SD standard deviation
a Worst Hurley stage of all regions. Hurley stage I: Localised formation of single or multiple abscesses without sinus tracts and scarring. Hurley 
stage II: Recurrent abscesses with sinus tract formation and scarring; single or multiple lesions. Hurley stage III: Diffuse involvement with inter-
connected tracts and abscesses
b Data missing for one adolescent
c Patients could have reported using pads in multiple areas. Data were not analysed for adults versus adolescents because the number of adoles-
cent patients was too small to provide meaningful information
d Includes groin
e “Flare” was as reported by patient or investigator and was not pre-defined in the protocol
Characteristics Adults
N = 529
Adolescents
N = 65
All patients
N = 594
Hurley  stagea
 I 28 (5.3) 12 (18.5) 40 (6.7)
 II 346 (65.4) 48 (73.8) 394 (66.3)
 III 155 (29.3) 5 (7.7) 160 (26.9)
ISH4 severity  scoreb [43]
 ≤ 3 (mild) 121 (22.9) 22 (34.4) 143 (24.1)
 4–10 (moderate) 147 (27.8) 20 (31.3) 167 (28.1)
 ≥ 11 (severe) 261 (49.3) 22 (34.4) 283 (47.6)
Age at start of HS symptoms, years (N = 528)
24.5 ± 12.3
(N = 65)
12.1 ± 3.4
(N = 593)
23.2 ± 12.3
Years from HS symptom onset to diagnosis (N = 527) (N = 65) (N = 592)
 Mean ± SD 8.3 ± 10.5 2.5 ± 3.3 7.7 ± 1.2
 Median (1st, 3rd quartiles) 4.1 (0.6, 12.2) 1.3 (0.3, 3.0) 3.7 (0.5, 10.8)
Family history of HS 159 (30.1) 23 (35.4) 182 (30.6)
HS lesion count (N = 529) (N = 64) (N = 593)
 Abscesses 3.7 ± 8.8 2.6 ± 7.7 3.6 ± 8.8
 Draining fistulas 2.6 ± 6.1 0.9 ± 2.0 2.4 ± 5.8
 Non-draining fistulas 6.7 ± 22.6 1.2 ± 2.6 6.1 ± 21.5
 Inflammatory nodules 7.1 ± 11.0 5.4 ± 7.4 6.9 ± 10.7
 Non-inflammatory nodules 6.9 ± 17.5 6.4 ± 24.9 6.9 ± 18.4
Used pads for lesion  drainagec – – 230 (38.7)
 Mammary – – 34 (14.8)
 Pelvicd – – 87 (37.8)
 Axilla – – 97 (42.2)
 Buttock – – 32 (13.9)
Number of HS  flarese per patient during previous 6 months (N = 529)
5.8 ± 9.5
(N = 64)
4.6 ± 5.6
(N = 593)
5.7 ± 9.1
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Fig. 1  Hidradenitis suppura-
tive lesion count by body area 
and Hurley stage. Mean total 
lesion count, by body area and 
Hurley stage: a adults and b 
adolescents. Mean abscess and 
inflammatory nodule and fistula 
counts, c overall and by body 
area and d by Hurley stage. 
aThe “other” category includes 
abdomen, back, chest exclud-
ing infra- and intermammary 
areas, face including ears and 
behind ears, genitals, left and 
right upper and lower extremi-
ties, neck, pubic region, scalp; 
bN = 187 for fistulas in the 
mammary area. Lesions include 
a, b abscess, inflammatory and 
non-inflammatory nodules, 
draining and non-draining fis-
tulas, hypertrophic scar caused 
by HS. c, d “Fistulas” includes 
fistulas and non-draining fistu-
las; “N” represents the number 
of patients in each Hurley stage 
who had any lesion present in 
the corresponding body area; 
used as denominator when 
calculating mean lesion count. 
SD is indicated under each data 
label appearing above each bar 
of the graphs. AN abscesses 
and inflammatory nodule, HS 
hidradenitis suppurativa, SD 
standard deviation
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history of inflammatory bowel disease (Crohn’s disease or 
ulcerative colitis), similar to other published rates [35–37].
Given the variety of contributors to the disease bur-
den in HS, as seen in this analysis and previous reports, a 
multidisciplinary and multimodal approach to treatment 
is necessary. Under-treatment of HS is a global problem, 
which is confirmed by this analysis. At baseline, aside 
from antibiotics, systemic treatments such as oral retinoids 
and immunosuppressants had been prescribed in a minor-
ity of patients (17.7% and 1.3%, respectively). During the 
majority of the study enrolment period (December 2013 
to December 2015), no biologic treatment was approved 
for HS. As such, reports at baseline of any biologic use 
for HS was low (5.5% of adults and no adolescents) and 
may not approximate biologic use post-approval of adali-
mumab; this is a potential limitation of this study. Pro-
cedural and surgical treatment of lesions is an important 
part of the HS treatment paradigm, especially as disease 
severity increases [12, 26, 38], as was observed in UNITE; 
50.0%, 67.8%, and 75.6% of patients with Hurley stages I, 
II, and III, respectively, reported prior procedures/surger-
ies. However, the high percentage of patients reporting 
a history of incision and drainage procedures, especially 
for patients with Hurley stage II or III disease (47.9% 
and 45.6%, respectively), suggests that disease in these 
patients is not adequately controlled; more aggressive sur-
gical procedures such as de-roofing and en bloc excision 
were performed in far fewer of these patients (23.6% and 
32.5% of patients with Hurley stage II and III disease, 
respectively).
Depression and anxiety are strongly associated with 
HS and are significant factors affecting quality of life for 
these patients [17, 18, 39, 40]. A retrospective case–con-
trol study reported that 58% of patients with HS had a psy-
chiatric disorder [22]. Psychiatric comorbidities reported 
in UNITE at baseline included 13.3% with depression and 
Table 4  Patients with scarring due to hidradenitis suppurativa for enrolled patients (N = 594)
Data are presented as N (%) unless otherwise indicated
a Includes intermammary and left and right inframammary areas
b Includes buttocks, inguinal fold, perianal, perineal, pubic, genital areas
c Includes left and right axilla areas
d Lists anatomic regions that are included in the body area labelled “Other”
e Excluding mammary, infra- and intermammary areas
f Including ears and behind ears
Scarring area Any scarring By Hurley stage
I (N = 43) II (N = 392) III (N = 159)
Entire body
 Overall, N = 594 542 (91.2) 2 (4.7) 381 (97.2) 159 (100.0)
 Adults, N = 529 491 (92.8) – – –
 Adolescents, N = 65 51 (78.5) – – –
Body area Any scarring Body area with scarring
1–25% 26–50% 51–75% 76–100%
Mammarya 152 (25.6) 106 (69.7) 29 (19.1) 11 (7.2) 6 (3.9)
Pelvic/pubic/genitalb 412 (69.4) 220 (53.4) 106 (25.7) 46 (11.2) 40 (9.7)
Axillac 361 (60.8) 195 (54.0) 86 (23.8) 37 (10.2) 43 (11.9)
Other body  aread
 Abdomen 81 (13.6) 60 (74.1) 16 (19.8) 4 (4.9) 1 (1.2)
 Back 36 (6.1) 27 (75.0) 4 (11.1) 3 (8.3) 2 (5.6)
 Cheste 14 (2.4) 9 (64.3) 3 (21.4) 2 (14.3) 0
 Facef 31 (5.2) 21 (67.7) 6 (19.4) 2 (6.5) 2 (6.5)
 Upper extremity, right 20 (3.4) 16 (80.0) 3 (15.0) 1 (5.0) 0
 Upper extremity, left 17 (2.9) 15 (88.2) 1 (5.9) 1 (5.9) 0
 Lower extremity, right 36 (6.1) 29 (80.0) 4 (11.1) 2 (5.6) 1 (2.8)
 Lower extremity, left 37 (6.2) 30 (81.1) 2 (5.4) 3 (8.1) 2 (5.4)
 Neck 36 (6.1) 24 (66.7) 9 (25.0) 2 (5.6) 1 (2.8)
 Scalp 12 (2.0) 7 (58.3) 5 (41.7) 0 0
Baseline Characteristics from UNITE Observational Registry of Hidradenitis Suppurativa in Clinical Practice
Table 5  Medical history of interest
Data are presented as N (%)
HS hidradenitis suppurativa
a Including Crohn’s disease and ulcerative colitis
b Also referred to as dyslipidaemia or hypercholesterolemia
c Excludes depression; includes anxiety. Some patients reported more than one “other cognitive psychiatric disorder”; those who experienced 
multiple disorders were counted only once. This could result in under-representation of incident disorders as the reported number only reflects 
the proportion of patients experiencing any cognitive/psychiatric disorder(s) other than depression
Body system Condition/diagnosis All patients
N = 594
Cardiovascular Hypertension 85 (14.3)
Anaemia 19 (3.2)
Peripheral vascular disease 11 (1.9)
Gastrointestinal Gastroesophageal reflux disease 31 (5.2)
Inflammatory bowel  diseasea 16 (2.7)
Integument Pilonidal cyst 42 (7.1)
Contracture/strictures due to HS scarring 27 (4.5)
Psoriasis 25 (4.2)
Severe acne 25 (4.2)
Acne conglobata 16 (2.7)
Pyoderma gangrenosum 6 (1.0)
Dissecting folliculitis 4 (0.7)
Metabolic Diabetes mellitus 54 (9.1)
Hyperlipidaemiab 35 (5.9)
Irregular menstrual cycles 32 (5.4)
Polycystic ovary syndrome 31 (5.2)
Neurologic and psychiatric Depression 79 (13.3)
Other cognitive or psychiatric  disorderc 57 (9.6)
Pulmonary Asthma 37 (6.2)
Table 6  Prior procedure and surgery for hidradenitis suppurativa
Data are presented as N (%)
ND-YAG neodymium-doped yttrium aluminum garnet
Adults
N = 529
Adolescents
N = 65
All patients
N = 594
All patients by Hurley stage
I, N = 40 II, N = 394 III, N = 160
Any procedure 383 (72.4) 25 (38.5) 408 (68.7) 20 (50.0) 267 (67.8) 121 (75.6)
 De-roofing 40 (7.6) 0 40 (6.7) 0 23 (5.8) 17 (10.6)
 En bloc excision 105 (19.8) 2 (3.1) 107 (18.0) 2 (5.0) 70 (17.8) 35 (21.9)
 Incision and drainage by patient 71 (13.4) 1 (1.5) 72 (12.1) 2 (5.0) 58 (14.7) 12 (7.5)
 Incision and drainage by physician 187 (35.3) 14 (21.5) 201 (33.8) 9 (22.5) 131 (33.2) 61 (38.1)
 Intralesional steroid injections 91 (17.2) 5 (7.7) 96 (16.2) 5 (12.5) 61 (15.5) 30 (18.8)
 Laser treatment,  CO2 9 (1.7) 1 (1.5) 10 (1.7) 0 6 (1.5) 4 (2.5)
 Laser treatment, ND-YAG 5 (0.9) 0 5 (0.8) 0 3 (0.8) 2 (1.3)
 Photodynamic therapy 5 (0.9) 0 5 (0.8) 0 2 (0.5) 3 (1.9)
 External-beam radiation therapy 1 (0.2) 0 1 (0.2) 0 0 1 (0.6)
 Other surgery or procedures 54 (10.2) 2 (3.1) 56 (9.4) 4 (10.0) 29 (7.4) 23 (14.4)
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9.6% with other cognitive/psychiatric disorders, including 
anxiety. However, the patient-reported Hospital Anxiety and 
Depression Scale outcome from UNITE showed that 58% 
of patients reported anxiety and 30% reported depression at 
baseline. This suggests that psychological disorders may be 
under-diagnosed and/or under-reported in this population 
and confirms the need for adequate multidisciplinary care 
and screening for these comorbidities.
Quality of life at baseline in UNITE was significantly 
impaired in adults, and scores worsened markedly as disease 
severity increased. Additional quality-of-life patient-reported 
outcomes from UNITE are addressed in a separate publica-
tion [27].
Limitations of this analysis include the bias that can be 
present in observational studies, including methods of patient 
selection, selective recall, inconsistent reporting, measure-
ment errors, and under-reporting, especially of information 
not apparent to the data collector, such as comorbidities and 
prior treatment [41]. Another potential limitation is the method 
of describing disease severity and the potential influence of 
disease severity on enrolment. Per the protocol, the original 
Hurley staging criteria [24] were used as the method for defin-
ing severity, which is not necessarily correlated to disease 
activity at any given time. A newer method of Hurley staging 
has since been published [42], in which Hurley IC and IIC are 
classified as “severe”, but this staging was not available at the 
time of data collection. In addition, while balancing of patients 
across Hurley stages was attempted, the vast majority enrolled 
had Hurley stage II and III disease; thus, their results may not 
be generalisable to the entire HS population. Although the 
majority of UNITE patients were enrolled in North American 
(68.9%) sites, these data contribute to the global characterisa-
tion of HS in patients in real-world clinical settings.
5  Conclusions
The UNITE baseline data confirm that overweight, obe-
sity, and smoking are common risk factors in patients with 
HS. The disease burden is high, reflected by the extent 
of scarring, frequency of disease flares (once monthly on 
average) despite treatment, and the significant comorbidity 
burden. Our results also confirm that patients can have HS 
for years before receiving an accurate diagnosis (8 years 
average overall) and that those with more severe disease 
often resort to surgery. The impact on quality of life and 
the challenging therapeutic management of HS often 
necessitate a multidisciplinary approach to care.
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